arlzAralez Pharmaceuticals Inc (NASDAQ:ARLZ) announced the availability of once-daily YOSPRALA™, the only prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI), in the U.S. YOSPRALA is indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. YOSPRALA is being promoted by 110 sales representatives in the U.S. and is currently available in the wholesale chain.

YOSPRALA is designed to support both cardio- and gastro-protection for at-risk patients through the proprietary Intelli-COAT™ system, which is formulated to sequentially deliver immediate-release omeprazole (40 mg) followed by a delayed-release, enteric-coated aspirin core in either 81 mg or 325 mg dose strengths.

“We are pleased to announce the commercial launch of YOSPRALA in the U.S. supported by our fully trained, 110 person sales force deployed to promote YOSPRALA to cardiologists and high prescribing primary care physicians,” said Adrian Adams, Chief Executive Officer of Aralez. “YOSPRALA, a product that is specifically designed to reduce aspirin intolerance and therefore potentially improve compliance to therapy, has the promise to benefit healthcare practitioners, payors and patients. We believe that YOSPRALA represents a significant market opportunity and will contribute to solidifying our core therapeutic anchor position in cardiovascular disease alongside Fibricor®.”(Original Source)

Shares of Aralez Pharmaceuticals closed last Friday at $4.85, up $0.02 or 0.41%. ARLZ has a 1-year high of $6.80 and a 1-year low of $3.10. The stock’s 50-day moving average is $5.28 and its 200-day moving average is $4.13.

On the ratings front, ARLZ has been the subject of a number of recent research reports. In a report issued on September 16, Chardan analyst Keay Nakae reiterated a Buy rating on ARLZ, with a price target of $10, which represents a potential upside of 106% from where the stock is currently trading. Separately, on the same day, Guggenheim’s Louise Chen reiterated a Buy rating on the stock and has a price target of $12.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Keay Nakae and Louise Chen have a total average return of -20.8% and -10.9% respectively. Nakae has a success rate of 31% and is ranked #4029 out of 4197 analysts, while Chen has a success rate of 39% and is ranked #4012.